Perspective Therapeutics, Inc. (CATX): Cash & Equivalents
$30.63M
As of 2025-12-31
$48.49M
As of 2026-06-30
+13.4%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.63M | -50.3% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $61.58M | +566.6% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $9.24M | -56.0% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $20.99M | n/a | 2024-03-28, Balance as of period end |
| 2022-06-30 | $55.89M | -12.4% | 2024-03-28, Balance as of period end |
| 2021-06-30 | $63.83M | n/m | 2022-09-28, Balance as of period end |
| 2020-06-30 | $2.39M | -55.1% | 2022-09-28, Balance as of period end |
| 2019-06-30 | $5.33M | +104.8% | 2021-09-27, Balance as of period end |
| 2018-06-30 | $2.60M | -56.2% | 2020-09-25, Balance as of period end |
| 2017-06-30 | $5.93M | -41.5% | 2019-09-27, Balance as of period end |
| 2016-06-30 | $10.14M | +94.0% | 2018-09-26, Balance as of period end |
| 2015-06-30 | $5.23M | -31.9% | 2017-09-28, Balance as of period end |
| 2014-06-30 | $7.68M | +164.8% | 2016-09-09, Balance as of period end |
| 2013-06-30 | $2.90M | +8.5% | 2015-09-14, Balance as of period end |
| 2012-06-30 | $2.67M | +26.5% | 2013-09-30, Balance as of period end |
| 2011-06-30 | $2.11M | n/a | 2012-10-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $30.63M | -50.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $257.62M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $75.60M | +244.5% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $58.45M | +52.4% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $57.22M | -68.7% |
Compare CATX, ARCT, NATR, DMRA side by side · Screen every company in Pharmaceutical Preparations ↗